In 2024, Núria Gavaldà was appointed Director of the Advanced Therapy Medicinal Products (ATMP) Manufacturing Platform at the Blood and Tissue Bank (BST) of Catalonia, a Substance of Human Origin (SoHO) establishment of the Government of Catalonia.

The BST ATMP Platform develops and manufactures innovative advanced therapy medicinal products within an academic environment, fostering scientific excellence and accelerating the translation of research into clinical applications.

She holds a PhD in Biology, a Postgraduate Degree in Pharmacovigilance from the University of Barcelona, and has completed the Executive Program for Healthcare Institutions at IESE Business School.

She worked as Research Associate at Cardiff University (United Kingdom) and was later appointed as Scientific Director at SOM Biotech, a Barcelona-based biotechnology company focused on drug repurposing. From 2014 to 2023, she was Director of Strategy at the Vall d’Hebron Research Institute (VHIR) in Barcelona, where she led strategic initiatives to strengthen research, innovation, and translational activities.